Lipinski B, Lipinska I, Nowak A, Gurewich V
J Lab Clin Med. 1977 Jul;90(1):187-94.
The present study demonstrates that the fibrinolytic activity is significantly increased and the level of plasminogen antiactivator diminished in the blood of patients with advanced liver cirrhosis and chronic aggressive hepatitis as compared with the values for healthy subjects. Total fibrinogen concentration was similar in patients and controls. However, electrophoresis of plasma with the use of SDS-polyacrylamide gel (3.5%) showed considerable differences in the composition of fibrinogen fractions. Lower molecular weight (LMW and LMW1) clottable protein was significantly (p less than 0.01) increased in the patients. In two out of 22 patients the higher molecular weight (HMW) fraction was virtually absent. In vitro incubation (37 degrees C for 48 hr) of diluted (1:10) plasma from a patient resulted in extensive degradation of a low-solubility fibrinogen fraction (HMW) previously added to the sample. No degradation was observed in any undiluted plasma samples. It is concluded that the increased concentration of lower-molecular-weight forms of clottable protein in the blood of patients with liver disease is probably related to increased in vivo degradation rather than abnormal synthesis. An association rather than a direct correlation with fibrinolytic activity was found.
本研究表明,与健康受试者相比,晚期肝硬化和慢性侵袭性肝炎患者血液中的纤溶活性显著增加,纤溶酶原抗激活剂水平降低。患者和对照组的总纤维蛋白原浓度相似。然而,使用SDS-聚丙烯酰胺凝胶(3.5%)对血浆进行电泳显示,纤维蛋白原组分的组成存在显著差异。患者中可凝性蛋白的低分子量(LMW和LMW1)显著增加(p<0.01)。22例患者中有2例几乎不存在高分子量(HMW)组分。对一名患者稀释(1:10)的血浆进行体外孵育(37℃,48小时),导致先前添加到样品中的低溶解度纤维蛋白原组分(HMW)大量降解。在任何未稀释的血浆样品中均未观察到降解。得出的结论是,肝病患者血液中可凝性蛋白低分子量形式浓度的增加可能与体内降解增加有关,而不是异常合成。发现与纤溶活性存在关联而非直接相关性。